Expert Interview
Discussing Keros Therapeutics' KER-050 and their ongoing phase 2 trials in Myelodysplastic syndromes (MDS)
Ticker(s): KROSInstitution: UCSD Moores Cancer Center
- Associate Professor of Medicine at UCSD and founder of the MDS Center of Excellence at UC San Diego Health.
- Specializes in the care of patients with myelodysplastic syndromes (MDS) and related blood disorders.
- Runs a research laboratory dedicated to the study of MDS with a focus on discovering disease features that can be used to personalize the care of patients with MDS.
- Research led to the development of clinic tests for mutations that help predict prognosis and individualize treatment options for patients; Current research involves investigating how acquired mutations in MDS patients are associated with their response to treatment with drugs like azacitidine and decitabine.
How many MDS patients do you treat?
Added By: wilson_adminHow has your experience with luspatercept been?
Added By: wilson_adminWhat are your opinion of the data shown so far for KER-050?
Added By: wilson_admin
Unmet medical need in low risk MDS in light of GERN data in RS negative population and Luspatercept data in the first line?
Given that KROS – does not allow in their current study for prior Lusparacept or Sotatercept Tx, azacytidine, decitabine, lenalidomide, includes ESA naïve --> is it fair to assume that KROS is preparing for a study in 1st line lower risk MDS? What would be the path forward in clinical development given that Luspatercept did not hit on RS negative population.
leaked abstracts on COMMANDS trial for EHA shows that the BMS missed in RS negative
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
